Berger Marc L, Doban Vitalii
Real-World Data and Analytics, Pfizer, Inc., 235 East 42nd Street, New York, NY 10017, USA.
J Comp Eff Res. 2014 Mar;3(2):167-76. doi: 10.2217/cer.14.2.
The intense competition that accompanied the growth of internet-based companies ushered in the era of 'big data' characterized by major innovations in processing of very large amounts of data and the application of advanced analytics including data mining and machine learning. Healthcare is on the cusp of its own era of big data, catalyzed by the changing regulatory and competitive environments, fueled by growing adoption of electronic health records, as well as efforts to integrate medical claims, electronic health records and other novel data sources. Applying the lessons from big data pioneers will require healthcare and life science organizations to make investments in new hardware and software, as well as in individuals with different skills. For life science companies, this will impact the entire pharmaceutical value chain from early research to postcommercialization support. More generally, this will revolutionize comparative effectiveness research.
随着互联网公司的发展而来的激烈竞争，开启了“大数据”时代，其特点是在处理大量数据方面有重大创新，并应用包括数据挖掘和机器学习在内的先进分析方法。医疗保健正处于自身的大数据时代边缘，监管和竞争环境的变化、电子健康记录的日益普及，以及整合医疗理赔、电子健康记录和其他新数据源的努力，都推动了这一进程。借鉴大数据先驱的经验，医疗保健和生命科学组织将需要在新硬件和软件以及具备不同技能的人员方面进行投资。对于生命科学公司而言，这将影响从早期研究到商业化后支持的整个制药价值链。更广泛地说，这将彻底改变比较效果研究。
